The biopharmaceutical industry serves the world’s need for treatments for a wide range of illnesses. The bioprocessing sector is a key part of the biopharmaceutical industry, manufacturing biological drugs to ensure safety and effectiveness. The scientific instrument industry plays a vital role in the bioprocessing market, with companies offering analytical techniques and products that can […]
The National Instituts of Health (NIH) has released the “2020–2030 Strategic Plan for NIH Nutrition Research,” developed by the NIH Nutritional Research Task Force. The report calls for research investments in Precision Nutrition. Unlike personalized nutrition or nutrigenomcis, Precision Nutrituion encompasses both internal and external contributions: diet, genetics, physical health, microbiome, metabolism, dietary habits, activity […]
In the IBO blog’s fourth look at coronavirus-related R&D funding, the focus is on announcements made in May. Governments continue to make large commitments, with funding ultimately designated for universities, research institutes, the private sector, and infectious disease research organizations that will coordinate efforts to funnel money to all three sectors. These organizations include CEPI […]
Clinical diagnostic testing has been a major bottleneck throughout the global response to the COVID-19 pandemic, with severe shortages of testing reagents, lack or slow adaptation of existing infrastructure to administer tests, and very rapidly growing demand that is outpacing supply. The extraordinary demand for COVID-19 testing has strained the production capabilities of vendors in […]
The development of cell and gene therapies has become an essential component of cancer and genetic disease research and treatment. Consequently, regulatory approvals for cell and gene therapy have begun to increase globally. As a result, cell and gene therapy research has expanded into other areas of medicine, such as treatments for autoimmune and dermatological diseases.
This is the third of IBO’s review of R&D investments related to COVID-19 (see March 27 and April 17). The outbreak has triggered a wide range of responses spanning immediate and long-term solutions. For R&D, spending priorities range from areas such as new diagnostic approaches and vaccine development to basic research in fields such as […]
The analytical and scientific instrument market in Europe is a compelling situation. According to IBO’s publisher Strategic Directions International (SDi) and part of Science and Medicine Group, prior to the COVID-19 pandemic, the industry’s recent performance in the region has been modest with periods of both enthusiastic and tepid demand. Despite the region’s strong presence […]
Demand for analytical and scientific instrumentation has grown in Asia Pacific, excluding China and Japan (Asia Pacific). Specifically, these products have been utilized to address issues such as climate change and an aging population food production and new energy sources. Analytical and scientific instrumentation vendors have responded to the demands via distribution by local companies […]
Marking another new step forward in more effective COVID-19 testing, as of April 2, the US FDA had approved three molecular point-of-care (POC) tests for COVID-19. The POC assays enable testing in patient care settings such as doctors’ offices and urgent care facilities. POC tests are one of the urgently needed solutions to address the […]
April 9, 2021 6:31 pm
March 29, 2021 6:26 pm
March 5, 2021 3:29 pm
Your Data and Privacy
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.